OLN324

DRUG3 trials

Sponsors

Ollin Biosciences, Inc.

Conditions

Diabetic Macular Edema (DME)Neovascular (Wet) Age-Related Macular DegenerationWet Age Related Macular DegenerationWet Age-related Macular Degeneration

Phase 1

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

CompletedNCT07484074

Ollin Biosciences, Inc.Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration

Start: 2025-02-12End: 2025-12-09Updated: 2026-03-19

Phase 3

Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)

Not yet recruitingNCT07816315

Ollin Biosciences, Inc.Wet Age Related Macular Degeneration

Start: 2026-10-15End: 2029-12-15Target: 500Updated: 2026-09-11

Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)

Not yet recruitingNCT07816289

Ollin Biosciences, Inc.Wet Age-related Macular Degeneration

Start: 2026-10-15End: 2029-12-15Target: 400Updated: 2026-09-11